Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly na ïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials

ConclusionIn these pooled analyses of SRL-na ïve patients receiving lanreotide depot, 39–42% achieved IGF-1 control and 31–35% achieved GH and IGF-1 control. Control rates within post-surgery cohorts did not differ markedly from those in corresponding de-novo cohorts.
Source: Pituitary - Category: Endocrinology Source Type: research